Predictive models for adolescent idiopathic scoliosis (AIS) frequently rely on radiographic measurements, exposing patients to cumulative radiation. Non-radiographic predictors such as passive range of motion (PROM) and 3D surface topography (3D ST) parameters remain underexplored. This study aimed to evaluate non-radiographic and radiographic variables associated with Cobb angle progression and develop stratified predictive models based on bracing status. Methods: An IRB-approved retrospective review of AIS patients aged 10–18 with radiographic and 3D ST measurements was performed. Demographic, clinical, 3D ST, and bracing variables were collected. Curve change was defined as the difference between earliest and most recent Cobb angles. Univariate linear regression evaluated predictors of magnitude of Cobb angle change. Results: Fifty-seven patients with mean age of 13.6 years were included (braced n = 37; non-braced n = 20). Greater scoliotic angle and lumbar range of motion were significantly associated with Cobb angle progression in the overall cohort (p < 0.05). Among non-braced patients, scoliotic angle, female sex, and lumbar range of motion remained significant predictors (p < 0.05). No significant predictors were identified in the braced cohort. Conclusion: Clinical assessments and 3D ST variables demonstrated associations with Cobb angle progression. These findings support development of radiation-free predictive models for AIS progression.
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe combined immunodeficiency (SCID). Since the initiation of newborn screening (NBS), survival rates have improved significantly, but the impact of HCT upon neurodevelopment for patients with SCID requires more investigation. We performed a cross-sectional study of subjects with SCID in North America to assess the impact of NBS, transplant conditioning regimen, and genotype on neurodevelopmental outcomes after HCT. 69 subjects with SCID from 17 PIDTC centers (excluding those with ADA deficiency), ages 6–16 years, received comprehensive standardized neurodevelopmental testing of cognitive, behavioral, and emotional function. Compared with the normative population, our subjects performed in the average range. We found no impact of NBS, chemotherapy conditioning, or genotype. Multivariate analysis revealed a significant decrease in IQ in subjects whose families earned <$50,000 per year. We recommend that children treated by HCT for SCID be monitored with periodic cognitive and behavioral assessments for deficits that could potentially impact long-term ND outcomes.